1
|
Viral agents (2nd section). Transfusion 2024; 64 Suppl 1:S19-S207. [PMID: 38394038 DOI: 10.1111/trf.17630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2023] [Accepted: 12/02/2023] [Indexed: 02/25/2024]
|
2
|
Martins ML, da Silva-Malta MCF, Araújo AL, Gonçalves FA, Botelho MDL, de Oliveira IR, Boy LDSMF, Moreira HM, Barbosa-Stancioli EF, Ribeiro MA, Chaves DG. A potent inflammatory response is triggered in asymptomatic blood donors with recent SARS-CoV-2 infection. Rev Soc Bras Med Trop 2022; 55:e02392022. [PMID: 36287506 PMCID: PMC9592101 DOI: 10.1590/0037-8682-0239-2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Accepted: 08/24/2022] [Indexed: 11/07/2022] Open
Abstract
Background: The inflammatory response plays a significant role in the outcome of coronavirus disease (COVID-19). Methods: We investigated plasma cytokine and chemokine concentrations in non-infected (NI), asymptomatic severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)-infected blood donors (AS), and patients with severe COVID-19 (SC). Results: The SC group showed significantly higher levels of interleukin 6 (IL-6), IL-10, and CCL5 than the AS and NI groups. The SC and AS groups had considerably greater CXCL9 and CXCL10 concentrations than the NI group. Only NI and infected people showed separate clusters in the principal component analysis. Conclusions: SC, as well as AS was characterized by an inflammatory profile.
Collapse
Affiliation(s)
- Marina Lobato Martins
- Fundação Centro de Hematologia e Hemoterapia de Minas Gerais/Hemominas, Belo Horizonte, MG, Brasil.
| | | | - Argus Leão Araújo
- Fundação Hospitalar do Estado de Minas Gerais, Hospital Eduardo de Menezes, Belo Horizonte, MG, Brasil.
| | - Fabíola Araújo Gonçalves
- Fundação Hospitalar do Estado de Minas Gerais, Hospital Eduardo de Menezes, Belo Horizonte, MG, Brasil.
| | - Maiara de Lourdes Botelho
- Fundação Hospitalar do Estado de Minas Gerais, Hospital Eduardo de Menezes, Belo Horizonte, MG, Brasil.
| | - Isabelle Rocha de Oliveira
- Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Departamento de Microbiologia, Laboratório de Virologia Básica e Aplicada, Belo Horizonte, MG, Brasil.
| | | | - Hélinse Medeiros Moreira
- Fundação Centro de Hematologia e Hemoterapia de Minas Gerais/Hemominas, Belo Horizonte, MG, Brasil.
| | - Edel Figueiredo Barbosa-Stancioli
- Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Departamento de Microbiologia, Laboratório de Virologia Básica e Aplicada, Belo Horizonte, MG, Brasil.
| | - Maísa Aparecida Ribeiro
- Fundação Centro de Hematologia e Hemoterapia de Minas Gerais/Hemominas, Belo Horizonte, MG, Brasil.
| | - Daniel Gonçalves Chaves
- Fundação Centro de Hematologia e Hemoterapia de Minas Gerais/Hemominas, Belo Horizonte, MG, Brasil.
| |
Collapse
|
3
|
SARS-CoV-2 and post-donation information: a one-year experience of the French haemovigilance network. BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE 2022; 20:362-373. [PMID: 35175185 DOI: 10.2450/2022.0266-21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Accepted: 12/10/2021] [Indexed: 12/19/2022]
Abstract
BACKGROUND There is growing evidence to support the hypothesis that SARS-CoV-2 is probably not transmissible by blood transfusion. In this study, we use the data gathered over one year by the French haemovigilance network on post-donation information related to SARS-CoV-2, and virological investigations on corresponding plasma to explore viral transmission by transfusion. MATERIALS AND METHODS Whenever a donor reported COVID-19 symptoms and/or a positive SARS-CoV-2 nasopharyngeal (NP) PCR test, information regarding diagnosis and symptoms was collected using a specific questionnaire, and repository plasmas were screened using the SARS-COV-2 R-GENE® assay (Biomérieux). RNA sequencing (Sanger and deep sequencing) and virus isolation on Vero E6 cells were applied in plasma from donors testing positive. RESULTS We investigated 1,092 SARS-CoV-2-related post-donation information (PDI) reports. PDI donors were younger than the global donor population and donated more often in the Paris region. Sixty-eight percent reported a positive NP real-time (RT)-PCR or antigenic testing and 22% of these also had symptoms at the time of testing. Thirty-seven (3.4%) donations tested positive for SARS-CoV-2 RNA, 11 (30%) were confirmed by another molecular assay, and 7 (19%) by sequencing, confirming low viral level. Most RNAemic blood donors donated in southern regions and in Paris. There was no difference in demographic data or duration parameter between RNAemic and non-RNAemic donors. Duration parameter was determined as the time elapsed between donation and: i) the onset of symptoms; ii) a positive NP RT-PCR; and iii) PDI. Cell culture experiments did not show any infectivity related to RNAemic plasmas. DISCUSSION SARS-CoV-2 RNA can be detected in a small fraction of blood donors with PDI, reporting very low levels of RNA. The corresponding plasma is probably not infectious. These findings highlight the value of haemovigilance and PDI to guide blood safety strategies.
Collapse
|
4
|
Santa Maria F, Huang YJS, Vanlandingham DL, Bringmann P. Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies. Pathogens 2022; 11:pathogens11050521. [PMID: 35631042 PMCID: PMC9147860 DOI: 10.3390/pathogens11050521] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2022] [Revised: 04/24/2022] [Accepted: 04/25/2022] [Indexed: 12/04/2022] Open
Abstract
No cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transfusion-transmitted infections (TTI) have been reported. The detection of viral RNA in peripheral blood from infected patients and blood components from infected asymptomatic blood donors is, however, concerning. This study investigated the efficacy of the amotosalen/UVA light (A/UVA) and amustaline (S-303)/glutathione (GSH) pathogen reduction technologies (PRT) to inactivate SARS-CoV-2 in plasma and platelet concentrates (PC), or red blood cells (RBC), respectively. Plasma, PC prepared in platelet additive solution (PC-PAS) or 100% plasma (PC-100), and RBC prepared in AS-1 additive solution were spiked with SARS-CoV-2 and PR treated. Infectious viral titers were determined by plaque assay and log reduction factors (LRF) were determined by comparing titers before and after treatment. PR treatment of SARS-CoV-2-contaminated blood components resulted in inactivation of the infectious virus to the limit of detection with A/UVA LRF of >3.3 for plasma, >3.2 for PC-PAS-plasma, and >3.5 for PC-plasma and S-303/GSH LRF > 4.2 for RBC. These data confirm the susceptibility of coronaviruses, including SARS-CoV-2 to A/UVA treatment. This study demonstrates the effectiveness of the S-303/GSH treatment to inactivate SARS-CoV-2, and that PRT can reduce the risk of SARS-CoV-2 TTI in all blood components.
Collapse
Affiliation(s)
| | - Yan-Jang S. Huang
- Department of Diagnostic Medicine/Pathobiology, Biosecurity Research Institute, Kansas State University, Manhattan, KS 66506, USA; (Y.-J.S.H.); (D.L.V.)
| | - Dana L. Vanlandingham
- Department of Diagnostic Medicine/Pathobiology, Biosecurity Research Institute, Kansas State University, Manhattan, KS 66506, USA; (Y.-J.S.H.); (D.L.V.)
| | | |
Collapse
|
5
|
Zhang Q, Ling S, Hu K, Liu J, Xu JW. Role of the renin-angiotensin system in NETosis in the coronavirus disease 2019 (COVID-19). Pharmacotherapy 2022; 148:112718. [PMID: 35176710 PMCID: PMC8841219 DOI: 10.1016/j.biopha.2022.112718] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 02/08/2022] [Accepted: 02/10/2022] [Indexed: 12/20/2022]
Abstract
Myocardial infarction and stroke are the leading causes of death in the world. Numerous evidence has confirmed that hypertension promotes thrombosis and induces myocardial infarction and stroke. Recent findings reveal that neutrophil extracellular traps (NETs) are involved in the induction of myocardial infarction and stroke. Meanwhile, patients with severe COVID-19 suffer from complications such as myocardial infarction and stroke with pathological signs of NETs. Due to the extremely low amount of virus detected in the blood and remote organs (e.g., heart, brain and kidney) in a few cases, it is difficult to explain the mechanism by which the virus triggers NETosis, and there may be a different mechanism than in the lung. A large number of studies have found that the renin-angiotensin system regulates the NETosis at multiple levels in patients with COVID-19, such as endocytosis of SARS-COV-2, abnormal angiotensin II levels, neutrophil activation and procoagulant function at multiple levels, which may contribute to the formation of reticular structure and thrombosis. The treatment of angiotensin-converting enzyme inhibitors (ACEI), angiotensin II type 1 receptor blockers (ARBs) and neutrophil recruitment and active antagonists helps to regulate blood pressure and reduce the risk of net and thrombosis. The review will explore the possible role of the angiotensin system in the formation of NETs in severe COVID-19.
Collapse
|
6
|
Le Cam S, Gallian P, Ricard C, Narboux C, Barlet V, Maugard C, Hauser L, Brisbarre N, Cappy P, Pillonel J, Laperche S, Morel P. Low rate of RNAemia in blood donations collected during the first wave of COVID-19 in France. Transfusion 2022; 62:633-640. [PMID: 35089597 DOI: 10.1111/trf.16812] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2021] [Revised: 01/03/2022] [Accepted: 01/04/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND To investigate the transmission of SARS-CoV-2 via blood, we conducted retrospective molecular screening in blood donated during the first pandemic peak in the two French regions with the highest community transmission. METHODS Archived plasma samples randomly selected from donations collected between 23 and 29 March, 2020, in Eastern and Northern regions of France were tested for SARS-CoV-2 RNA in minipools of 4 donations (MP4) using the Grifols ProcleixSARS-CoV-2 assay. Reactive MP4 and the 4 corresponding plasmas were further tested with alternative RT-PCRs and sequencing. Testing for SARS-CoV-2 antibodies and in-vitro infectivity in cell culture were also performed. RESULTS Among the 2,818 MP4 (corresponding to 9,672 donations) tested for viral RNA, 5 were weakly reactive. Among the 20 plasmas included in these 5 MP4, one presented low-level reactivity with RT-PCRs and Procleix SARS-CoV-2 and was confirmed on sequencing. The estimated prevalence was 1.03/10,000 (95% CI 0-3.1). The 20 plasmas were antibody non-reactive and none of them showed cytopathic effects in cell-culture. When recalled, the index-donor declared having had symptoms compatible with SARS-CoV-2 infection a few days after donation. The two immunocompromised recipients transfused with red blood cells and an inactivated pooled platelet product did not develop COVID-19. CONCLUSION Our results indicated a low prevalence of SARS-CoV-2 RNA in the plasma of asymptomatic blood donors during the pandemic peak and no evidence of infectivity in vivo and in vitro. The transfusion risk remains theoretical and does not justify the implementation of SARS-CoV-2 NAT for blood donations. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Sophie Le Cam
- Etablissement Français du Sang, Centre Pays de la Loire, Angers, France
| | - Pierre Gallian
- Unité des Virus Émergents (UVE: Aix-Marseille Université - IRD 190 - Inserm 1207 - IHU Méditerranée Infection), Marseille, France.,Etablissement Français du Sang Provence Alpes Côte d'Azur et Corse, Marseille, France
| | - Celine Ricard
- Etablissement Français du Sang Hauts de France Normandie, Loos, France
| | - Céline Narboux
- Etablissement Français du Sang Hauts de France Normandie, Loos, France
| | - Valérie Barlet
- Etablissement Français du Sang Auvergne Rhône Alpes, Metz, Tessy, France
| | - Claude Maugard
- Etablissement Français du Sang Occitanie, Montpellier, France
| | - Lisette Hauser
- Etablissement Français du Sang Ile de France, Ivry, France
| | - Nadège Brisbarre
- Unité des Virus Émergents (UVE: Aix-Marseille Université - IRD 190 - Inserm 1207 - IHU Méditerranée Infection), Marseille, France.,Etablissement Français du Sang Provence Alpes Côte d'Azur et Corse, Marseille, France
| | - Pierre Cappy
- Centre National de Référence Risques Infectieux Transfusionnels, Institut National de la Transfusion Sanguine, Paris, France
| | - Josiane Pillonel
- Santé publique France, Département des maladies infectieuses, Saint-Maurice, France
| | - Syria Laperche
- Centre National de Référence Risques Infectieux Transfusionnels, Institut National de la Transfusion Sanguine, Paris, France
| | - Pascal Morel
- Etablissement Français du Sang, La Plaine St-Denis, France.,UMR 1098 RIGHT INSERM Université de Franche-Comté Etablissement Français du Sang, Besançon, France
| |
Collapse
|